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Competency for Nonsense-Mediated Reduction in Collagen X mRNA
Is Specified by the 30 UTR and Corresponds to the
Position of Mutations in Schmid Metaphyseal Chondrodysplasia
Jacqueline T. Tan,1 Friederike Kremer,1 Susanna Freddi,1 Katrina M. Bell,1 Naomi L. Baker,1
Shireen R. Lamande´,1,2 and John F. Bateman1,2,*
Nonsense-mediated decay (NMD) is a eukaryotic cellular RNA surveillance and quality-controlmechanism that degradesmRNA contain-
ing premature stop codons (nonsense mutations) that otherwise may exert a deleterious effect by the production of dysfunctional trun-
cated proteins. Collagen X (COL10A1) nonsense mutations in Schmid-type metaphyseal chondrodysplasia are localized in a region
toward the 30 end of the last exon (exon 3) and result in mRNA decay, in contrast to most other genes in which terminal-exon nonsense
mutations are resistant to NMD. We introduce nonsense mutations into the mouse Col10a1 gene and express these in a hypertrophic-
chondrocyte cell line to explore the mechanism of last-exon mRNA decay of Col10a1 and demonstrate that mRNA decay is spatially
restricted to mutations occurring in a 30 region of the exon 3 coding sequence; this region corresponds to where human mutations
have been described. This localization of mRNA-decay competency suggested that a downstream region, such as the 30 UTR, may play
a role in specifying decay of mutant Col10a1mRNA containing nonsense mutations. We found that deleting any of the three conserved
sequence regions within the 30 UTR (region I, 23 bp; region II, 170 bp; and region III, 76 bp) preventedmutantmRNA decay, but a smaller
13 bp deletion within region III was permissive for decay. These data suggest that the 30 UTR participates in collagen X last-exon mRNA
decay and that overall 30 UTR conﬁguration, rather than speciﬁc linear-sequencemotifs,may be important in specifying decay ofCol10a1
mRNA containing nonsense mutations.Because mutations that introduce premature stop codons
have been estimated to account for approximately one-
third of inherited genetic disorders,1,2 RNA surveillance
and quality control imposed by the NMD process is of fun-
damental importance in the molecular pathology of many
diseases. Themolecular basis ofNMDhas thusbeen the sub-
ject of intense interest, and many components have been
identiﬁed. In the classical model, the mammalian RNA
surveillance machinery is an integrated component of the
processes of RNA splicing, transport from the nucleus,
and translation in the cytoplasm.3–11 During pre-mRNA
splicing, a complex of proteins is deposited ~20 nucleotides
upstreamof exon-exon junctions. This exon-junction com-
plex (EJC)marks the site of intron excision and is composed
of a range of proteins involved in splicing,mRNA transport,
and NMD. During a proposed initial ‘‘pioneer’’ round of
translation, the ribosome displaces these EJC proteins as
it encounters them, continuing along the mRNA until
a stop codon is recognized, triggering the recruitment of
another RNA-binding-protein assembly including the
translation release factors. If there is no EJC downstream
of this surveillance-protein complex, such as occurs in the
last exon of genes, the stop codon is recognized as the cor-
rect stop, and normal termination proceeds. However, if
the stop codon is upstreamof an EJC, and thus located prior
to the terminal exon, it is identiﬁed as ‘‘premature.’’ In this
situation, communication between the surveillance com-
plex and the EJC targets the mRNA containing the
premature stop codon for NMD. In our previous studies
on nonsense mutations in the human collagen X gene,COL10A1, we found preliminary evidence that nonsense-
containing collagen XmRNA is degraded. Collagen X is ex-
pressedonly inhypertrophic cartilage, andmutations cause
Schmid-type metaphyseal chondrodysplasia (MCDS; MIM
#156500).12,13 Two heterozygous nonsense mutations,
COL10A1W611X and Y632X, which are 210 bp and 147 bp,
respectively, upstream of the normal stop codon led to
decay of the mutant mRNA in the affected cartilage tis-
sue.14,15 Other recent studies have demonstrated that a
premature termination at codon 663 (54 bp upstream of
the normal stop) also triggers COL10A1 mRNA decay.16
These ﬁndings were surprising in light of the fact that these
mutations reside within the terminal exon, exon 3, and
thus would not be expected to result in NMD because of
the absence of a downstream EJC. Our studies also demon-
strated that mRNA decay can be cell speciﬁc because decay
of nonsense-containing human COL10A1 mRNA only oc-
curred in cartilage cells and not in lymphoblasts and bone
cells from the patients.15 These two unusual aspects of the
nonsense-mediated reduction in abundance of COL10A1
mRNA fall outside the parameters of the classical NMDpro-
cess and raise critically important questions about the
nature of COL10A1mRNA decay. Because similar processes
may also play a role in the decay of nonsense mRNA pro-
duced by other genes, a better understanding of collagen
X mRNA decay should provide a more comprehensive un-
derstanding of the mechanistic complexities of mRNA-
surveillance pathways.
For exploration of the molecular determinants of colla-
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Figure 1. Col10a1 Gene Organization
The three exons of Col10a1 are drawn as
rectangles, whereas the introns are de-
noted by lines. The poly(A) signal in the
30 UTR is AATAAA. The sizes of the introns
and exons are shown in bp under the gene.
The normal termination is codon 681, and
the location of the engineered mutations
is shown above the gene. The distance up-
stream to the normal stop codon is shown
in bp below the engineered premature
stop codons. The coding region arising
from exon 2 and 3 is denoted by the filled
regions of the exons. The region where
MCDS patient mutations are clustered
(hatched) corresponds to the location of
the engineered mutations 632X, 651X, and 663X (asterisks). In the lower part of the diagram, the corresponding parts of the mRNA
are shown with the regions coding for the protein NC2, triple helical, and NC1 trimerization domain indicated.mutationswere engineered into amouseCol10a1 gene con-
struct.17 This construct contained all three exons, 2 kb of 50
promoter sequence, and 1.3 kb of 30 ﬂanking sequence in-
cluding the entire 30 UTR (Figure 1). Speciﬁc mutations in
Col10a1 were produced by overlap extension PCR as previ-
ously described.18 We sequenced constructs to ensure that
the correct mutations were introduced and that there
werenoPCRerrors. Theﬁnding thatCOL10A1mRNAdecay
was cell speciﬁc, only occurring in cartilage cells expressing
collagen X,15 necessitated the use of a mouse hypertrophic
cartilage cell line for our expression studies. We used the
mouse MCT hypertrophic-chondrocyte cell line (SV40
temperature-sensitive large T antigen transformed)19 be-
cause it expresses endogenous collagen X and thus should
have the capacity to direct collagen X nonsense mRNA
decaywhen the cell line is grown at thenonpermissive tem-
perature (37C). MCT cells maintained in Dulbecco’s mod-
iﬁed Eagle’s Medium containing 10% fetal-bovine serum
were grown to ~70% conﬂuence and cotransfected with
Col10a1 premature-stop-codon mutant constructs and
pGK-Hygro with FuGENE 6 transfection reagent (Roche)
as previously described.20 Cells were selected and main-
tained with 150 mg/ml hygromycin B (Roche), and individ-
ual clones were isolated and expanded into cell lines. To as-
sessmRNAdecay,we grew cells for 7 days at 37Cand added
ascorbic acid to a ﬁnal concentration of 0.25 mM on days
6 and 7. Cells were then preincubated for 6 hr with and
without 100 mg/ml cycloheximide (Sigma), an inhibitor of
NMD,15,21 prior to RNA isolation (RNeasy total RNA kit,
QIAGEN). Because of the low levels of collagen X expres-
sion, the ratio of mutant to endogenous collagen X mRNA
was measured by an allele-speciﬁc primer extension assay
(Table 1) as previously described.15 A protection of mutant
mRNA produced by the transfected Col10a1 gene relative
to the endogenouswild-type collagenXmRNA in the cyclo-
heximide-treated cells was taken as a measure of the extent
of decay of the mutant mRNA.15 To overcome clonal vari-
ability in expression levels of the endogenous and trans-
fected Col10a1, and to ensure that a signiﬁcant proportionThe Aof the clones analyzed for mRNA-decay competency were
expressing the appropriate hypertrophic-chondrocyte phe-
notype, we analyzed a large number of individual clonal
lines for each construct.
The data for constructs containing premature termina-
tion mutations at codons 632, 651, and 663 (147 to 54 bp
upstream of the normal termination codon; Figure 1)
corresponding to characterized MCDS mutations13 are
shown in Figures 2A–2C. The analysis of multiple trans-
fected clones demonstrated that cycloheximide pretreat-
ment resulted in a signiﬁcant protection of the mutant
mRNA relative to the wild-type (mean protection 200%–
300%), clearly demonstrating that mRNA decay occurred
for these three MCDS mutations. Because previous studies
have directly shown that the 632 and 651 nonsense muta-
tions result in mRNA decay in MCDS cartilage in vivo,14–16
our data conﬁrmed that mRNA decay also occurs for non-
sense mutations in this region of the mouse gene and
validated the use of this system for detailed studies of the
mRNA-decay competency of Col10a1 premature-termina-
tion-codon mutations. The 30 boundary of this decay-
competent region was assessed by transfection of MCT
chondrocytes with a construct containing a nonsense
mutation at codon 674, which is 21 bp upstream from
the normal 681 stop. With this construct, none of the
clones showed a protection with cycloheximide, demon-
strating that mRNA decay did not occur for premature ter-
mination codons immediately upstream of the normal
stop (Figure 2D). The presence of this 30 mRNA-decay
immune region was conﬁrmed by recent studies in a trans-
genicmouse in whichCol10a1with a 13 bp deletion result-
ing in premature stop at codon 672 was not subject to
mRNA decay, and themutant protein with a short C-termi-
nal truncation was expressed in mouse hypertrophic carti-
lage.22 This immunity to nonsence mutant RNA decay
may be due to the spatial relationship of this region’s
premature stop codons proximal to the normal stop with
putative downstream elements that may be involved
with regulating type X collagen mRNA decay.merican Journal of Human Genetics 82, 786–793, March 2008 787
Table 1. Primers Used in RT-PCR and Allele-Specific Primer Extension
Mutation Forward Primer (50 to 30) Reverse Primer (50 to 30) Extension Primer (50 to 30)
G174X TAAGAGGAGAACAAGGC TTGTGCACCCTTCTCTC TTGTGCACCCTTCTCTC
G308X TTCCAGGCCCTCAAGGTCCC ACCAGCAGGTCCCCTTTGTC ACCAGCAGGTCCCCTTTGTC
G407X AAGGTGAGATAGGTCTAGTTGG ACTCCAGGATCACCTTTTTGT ACTCCAGGATCACCTTTTTGT
G502X GGCAGGTCCAAGAGG CTGGGAGACCAGGTTCTC CTGGGAGACCAGGTTCTC
Q518X TTGGCCCTGTAGGAGCTAAAG CATCAGGCATGACTGCTT CATCAGGCATGACTGCTT
Y582X GTACAATAGGCAGCAGCATTA TAGAAGTGAGGAAACTTGGTC GTACAATAGGCAGCAGCATTA
Y632X GGCAGGTCCAAGAGG AATGTCAGCCTTTAAGGGTG TGAGTACAGCAAAGGCTA
W651X GGCAGGTCCAAGAGG AATGTCAGCCTTTAAGGGTG ACAGAAAATGACCAGGTATG
Y663X GGCAGGTCCAAGAGG AATGTCAGCCTTTAAGGGTG AGAATCAAACGGCCTCTA
G674X GGCAGGTCCAAGAGG AATGTCAGCCTTTAAGGGTG TGGGAGCCACTAGGAATC
Y632X-DI TGAGTACAGCAAAGGCTA AATGTCAGCCTTTAAGGGTG TGAGTACAGCAAAGGCTA
Y632X-DII TGAGTACAGCAAAGGCTA AATGTCAGCCTTTAAGGGTG TGAGTACAGCAAAGGCTA
Y632X-DIII TGAGTACAGCAAAGGCTA AATGTCAGCCTTTAAGGGTG TGAGTACAGCAAAGGCTA
Y632X-DIII[AU] TGAGTACAGCAAAGGCTA AATGTCAGCCTTTAAGGGTG TGAGTACAGCAAAGGCTA
Total RNA (200 ng) from MCT cells transfected with mutant Col10a1 constructs was used as a template for RT-PCR with the primers shown above. The cDNA
fragment was gel purified, and 5 ng used as a template for allele-specific primer extension. Primers used in the primer-extension reactions were designed to
anneal one base 50 to the mutation so that extension with specific a-33P-dNTPs would thus discriminate between the mutant and endogenous mRNAs. The
extension reactions were carried out at 95C for 1 min, 50C (G407X and Q518X), 55C (G174X), 56C (W651X), and 60C (G308X, G502X, Y582X, Y632X,
Y663X, G674X, Y632X-DI, Y632X-DII, Y632X-DIII, and Y632X-DIII[AU]) for 2 min, and 72C for 1 min in 10 ml of 10 mM Tris/HCl (pH 8.3) containing 50 mM
KCl, 1.5 mM MgCl2, 0.01% (w/v) gelatin, 1 mM primer, and 1 mCi of [a-
33P]-dCTP, dGTP, or dATP (Perkin Elmer) in the absence of nonradioactive dNTPs. The
products were analyzed on 15% (w/v) denaturing polyacrylamide gels containing 7 M urea, and the radioactivity incorporated into the extended products
was quantified with a phosphor imager (Molecular Dynamics) with the program ImageQuant TL (Amersham Biosciences).To explore the 50 range of mRNA-decay competency, we
examined nonsense codons at 174, 308, 407, 502, 518,
and 582 (1521 bp to 297 bp upstream of the normal stop;
see Figure 1). These are 50 of the region in exon 3 where
MCDS mutations have been characterized.13 For all these
mutations, cycloheximide did not cause protection of the
mutant mRNA, indicating that mRNA decay did not occur
for these stop-codon mutations, which are more than
~300 bp upstream of the normal stop (Figures 3A–3F).
Our data demonstrated that the region of the Col10a1
mRNA competent for nonsense mutant mRNA decay was
restricted to a relatively small region of exon 3 that corre-
sponds to the region of the gene containing the known
MCDS nonsense mutations (Figure 4). Nonsense muta-
tions beyond this region in Col10a1, either immediately
downstream at codon 674 or upstream from codon 582
to at least codon 174, did not undergo mRNA decay (Fig-
ure 4). Although there are some examples of polarity in
NMD susceptibility along genes,23–25 the complete restric-
tion of nonsense-mRNA-decay competency to a very local-
ized region of the last exon of Col10a1 is unique and
further suggests previously unrecognized mechanisms of
mRNA-decay speciﬁcation.
A possible mechanism of Col10a1mRNA destabilization,
consistent with such a localized region of decay compe-
tence, could involve the disturbance of a putative mRNA
stability element in this region of exon 3. Although there
is no evidence suggesting the presence of such an element
in Col10a1mRNA, there are several examples, such as elas-
tin26 and Cited-2,27 in which sequence elements within the
mRNA coding sequence are involved in controlling mRNA
decay in response to TGFb. If such an element existed in
Col10a1, it would be expected that missense and other mu-788 The American Journal of Human Genetics 82, 786–793, March 2tations in this critical region would also disturb such regu-
latory sequences and cause mRNA decay. However, recent
studies on a MCDS mouse model in which a heterozygous
N617K missense mutation has been knocked into Col10a1
showed equal abundance of the wild-type and N617K
allele mRNAs (H. Rajpar and R. Boot-Handford, personal
communication). Furthermore, studies on MCDS patient
cartilage mRNA containing a heterozygous S600P muta-
tion shows no mRNA decay of the mutant mRNA.28 These
data demonstrate that the presence of a mutation in this
region, per se, does not cause mRNA decay and that the
mutant mRNA decay is nonsense mediated.
The most likely reason for the inability of mutations in
these upstream regions to elicit mRNA decay is that they
are unable to be recognized by the RNA surveillance ma-
chinery. In yeast, there is a 150–200 bp limit in the dis-
tance from a downstream element and the stop codon
for functional NMD.29 In mammals, little is known about
the maximum distance from the EJC to the premature
stop codon. Data showing that the limit for TPI is 559
bp,30 whereas in BRCA1 stop codons as far as 3395 bp up-
stream result in NMD,31 suggest that there may not be
a global maximum limit. The out-of-range limit may be
gene speciﬁc and controlled by other regulatory elements
or by the ability of the local RNA structure to allow juxta-
position of the critical surveillance-machinery compo-
nents. In the intron-less genes in yeast, it has been shown
that 30 downstream sequence elements substitute for the
EJC to deﬁne premature termination codons, target the
transcript for NMD,29 and deﬁne the out-of-range limit,
and it is tempting to suggest that a downstream element
may thus be involved in Col10a1 mRNA decay. The loca-
tion of the mRNA-decay-competent region of exon 3,008
encompassing ~50 to <300 bp upstream of the normal
stop, suggests that the adjacent 30 UTR could contain the
downstream element(s) regulating Col10a1 mRNA decay.
Furthermore, recent studies have shown that a properly
conﬁgured 30 UTR is important for correct translation ter-
mination and mRNA stability.32
Figure 2. Premature Stop Codons Lo-
cated in the MCDS Mutation Region
Cause mRNA Decay
Each data point represents the determina-
tion of the change in the ratio of the
mRNA of transfected mutant construct
(mut) to the endogenous normal collagen
X mRNA (WT) caused by cycloheximide
treatment of an individual stably trans-
fected MCT clone expressing Y632X (A),
W651X (B), Y663X (C), and YG674X (D).
The dotted horizontal line denotes no
change in the mut:WT ratio resulting from
treatment of the cells with the NMD inhib-
itor cycloheximide. An increase in the
mut:WT mRNA ratio after cycloheximide
treatment indicates that the transfected
construct undergoes mRNA decay. The
mean of the percentage change in the
mut:WT ratio caused by cycloheximide
treatment is denoted by the solid horizon-
tal line. Y632X, W651X, and Y663X non-
sense codons all lead to Col10a1 mRNA de-
cay, whereas G674X does not cause mRNA
decay.
Figure 3. Nonsense Mutations Upstream of the MCDS Region Do Not Lead to mRNA Decay
Each data point represents the determination of the change in the ratio of the mRNA of transfected mutant construct (mut) to the en-
dogenous normal collagen X mRNA (WT) caused by cycloheximide treatment of cells stably transfected with G174X (A), G308X (B), G407X
(C), G502X (D), Q518X (E), and Y582X (F). The dotted horizontal line denotes no change in the mut:WT ratio resulting from treatment of
the cells with the NMD inhibitor cycloheximide. The mean of the percentage change in the mut:WT ratio caused by cycloheximide treat-
ment is denoted by the solid horizontal line. All constructs show no effect of cycloheximide treatment on the mean mut:WT ratio, dem-
onstrating that the G174X, G308X, G407X, G502X, Q518X, and Y582X Col10a1 constructs do not undergo mRNA decay.
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Terminal exon nonsense-mediated reduction in collagen
X abundance could also, in principle, be explained by the
classical model of NMD if exon 3 was not the terminal
exon and an unrecognized spliceable intron lay down-
stream of the normal stop codon. If this was the case, the
putative intron would have to be within 50 bp of the nor-
mal stop to conform to the ‘‘50–55 nt-rule,’’33 so that the
wild-type transcript would not be targeted for NMD. There
is no bioinformatic evidence for a downstream intron in
the type X collagen gene, and direct RT-PCR ampliﬁcation
of the 30 UTR demonstrated only the expected single 30
UTR amplicon (data not shown) ruling out the presence
of a downstream spliceable intron.34
Ourdata suggest that the30UTRofCol10a1 could contain
themolecular trigger, other than a downstream EJC, to pro-
vide the crucial additional signal for decayofnonsense-con-
tainingmRNA.Col10a1has a long 30 UTR (993 bp), and bio-
informatic analysis revealed that it contains three regionsof
homology strongly conserved across species, suggesting
that these may have important biological roles (regions I,
II, and III). Region I (23 bp) has 91.3% homology between
human andmouse Col10a1, region II (170 bp) has 87% ho-
mology, and region III (76 bp) has 86% homology. Region
III was found to contain a 13 bp AU-rich region, which
have been shown in other genes to play a role in regulating
mRNA stability.35 To determine whether these conserved 30
UTR regions were involved in specifying NMD, we deleted
them individually from the Col10a1 construct containing
themRNA-decay-competent632Xstopmutation(Figure5).
Deletions of region I (23 bp; 632X-DI), region II (170bp;
632X-DII), or region III (76 bp; 632X-DIII) were produced
along with a further region III deletion in which only the
13 bp AU-rich region (632X-DIII[AU]) was removed. Trans-
fection of these into MCT chondrocytes resulted in the
abrogation of the mRNA-decay competency of the 632X
mutant construct when any of the three homologous do-
mains (I, II, or III) were removed (Figures 6A–6C), clearly
demonstrating that the 30 UTR is critical in speciﬁcation
of Col10a1 nonsense mRNA decay (Figure 4). Interestingly,
the deletion of only the AU-rich region (13 bp) within re-
gion III did not abolish the ability of the 632X mutant
mRNA to undergo decay (Figure 6D). The mechanism of
how the 30 UTR directs mRNA decay is not known and is
the subject of current detailed study, but our data suggest
that because all three deletions (regions I, II and II; Figure 5)
in the 30 UTR lead tomRNA-decay incompetency, it is likely
that disturbance to the structure or conﬁguration of the 30
UTR,32 rather than thedeletion of a speciﬁc linear-sequence
motif, is the underlying cause of the inhibition ofNMD. Re-
cently, a mechanism for nonsense-mutation-containing
mRNA degradation, speciﬁed by the 30UTR, called Staufen
1-mediated mRNA decay (SMD) has been described.36,37
SMDoccurs for the cohort of genes that bind Stau-1 in their
30 UTR, suggested to be ~1% of the HeLa cell transcrip-
tome.36 Stau-1 binding to double-stranded RNA structures
in the 30 UTR recruits the NMD factor Upf1 and initiates
SMD of transcripts that have termination codons more
than ~25 bp upstream of the Stau-1-binding region.
Whether such a Stau-1 mechanism is involved in Col10a1
mRNA decay is not yet known; however, current evidence
indicates that SMD is not limited to premature termination
codons in only restricted regions of the gene,37 as we ob-
served for Col10a1 (Figure 4), making it unlikely that SMD
is involved in the decay of nonsense-containing Col10a1
transcripts. Further detailed studies will test this and ex-
plore the nature of the speciﬁcation of Col10a1 mRNA by
the 30 UTR.
Nonsense-mediated mRNA decay is a fundamentally
important process in inherited genetic diseases and in
the regulation of normal protein expression. Our studies
have revealed surprising mechanistic features of the decay
Figure 4. Col10a1 Nonsense mRNA
Decay
The localization of the premature termina-
tion codons that cause mRNA decay are
shown by the filled rectangle below the di-
agram of the Col10a1 mRNA. Regions that
are resistant to nonsense mRNA decay are
designated with open rectangles. The cor-
responding region of the mRNA that con-
tains the human MCDS mutations is desig-
nated by the hatching. The arrow connecting the 30 UTR to the mRNA-decay-competent domain represents these studies’ conclusion that
implicates the 30 UTR in specifying mRNA decay for premature termination mutations localized in this region of COL10A1.
Figure 5. Diagrammatic Representation of the 30 UTR Dele-
tions
Three highly homologous regions (I, II, and III) were individually
deleted in the Y632X construct. The cross-hatched rectangles show
the corresponding deletions made in Y632X-DI, Y632X-DII, and
Y632X-DIII. Numbers under the rectangles indicate the distance
(bp) downstream of the normal stop codon. A further subdeletion
of an AU-rich region found in region III was also created (Y632X-
DIII[AU]).
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Figure 6. The 30 UTR Is Important for
Decay of Col10a1 Nonsense mRNA
Each data point represents the determina-
tion of the change in the ratio of the
mRNA of transfected mutant construct
(mut) to the endogenous normal collagen
X mRNA (WT) caused by cycloheximide
treatment of cells stably transfected with
an mRNA-decay-competent Y632X con-
struct (see Figure 2A) with further muta-
tions in the 30 UTR. Y632X-DI (A), Y632X-
DII (B), and Y632X-DIII (C) abolished
Y632X mRNA decay because cycloheximide
treatment now did not affect the ratio of
mut:WT collagen X mRNA. Deletion of
a 13 bp AU-rich region Y632X-DIII[AU]
(D) does not affect mRNA decay of Y632X.
The dotted horizontal line denotes no
change in the mut:WT ratio resulting from
treatment of the cells with the NMD inhib-
itor cycloheximide. The mean of the per-
centage change in the mut:WT ratio caused
by cycloheximide treatment is denoted by
the solid horizontal line.of Col10a1 mRNA containing nonsense mutations in the
terminal exon such as chondrocyte speciﬁcity15 and the
involvement of the 30 UTR in mRNA-decay speciﬁcation.
It is possible that this 30 UTR-directed last-exon mRNA de-
cay could represent a crucial ‘‘failsafe-RNA surveillance’’
mechanism for genes, such as Col10a1, which have large
terminal coding exons. Further deﬁnition of themechanis-
tic features of Col10a1 nonsense mRNA decay should be
informative in deﬁning the molecular complexity of this
important quality-control process.
Our new data deﬁning the mouse Col10a1 regions that
arenonsensemRNAdecay competent alsoprovoke specula-
tion about the molecular pathology of MCDS caused by
nonsense mutations. It is clear that if nonsense mutations
were upstream of the mRNA-decay-susceptible region in
Col10a1 (Figure 4), that is, if they were more than ~300 bp
upstream of the normal stop codon, they would not be
subject to surveillance and would produce truncated colla-
gen Xwith little or no NC1 domain. The carboxyl-terminal
NC1 domain of collagen X has been shown in numerous
studies to be essential for the interaction of the subunits
and trimerization of the collagen X molecule.20,38–40 Fur-
thermore, our previous studies with in vitro expression of
collagen X constructs with sequential C-terminal trunca-
tions have shown that a protein region corresponding to
codons 589–601 is absolutely necessary for the initiation
of collagen X trimer assembly, and without this region,
the truncated collagen X does not trimerize and, most im-
portantly, does not interfere with the efﬁciency of normal
allele collagenXprotein trimerization.39 These data suggest
that truncated proteins that donot contain this region, that
is, those that are produced by stop mutations upstream of
approximately codon 589, would not associate and would
probably be rapidly degraded intracellularly,20 resulting inThe Ahaploinsufﬁciency andnodominant interference of assem-
bly of the normal allele product. Because no MCDS non-
sense mutations have been found in these upstream re-
gions, it seems likely that such mutant collagen X is
innocuous and tolerated by the cartilage cells and does
not result in a clinical phenotype. Although it is also for-
mally possible that such severely truncated proteins result
in a more severe cartilage phenotype via an unexpected
intracellular gain-of-function activity, no mutations in
these upstream regions of Col10a1 have been found in pa-
tients with more severe growth-plate cartilage phenotypes
(J.F.B., unpublished data).
The upstream cutoff for the stop codons thatwould cause
dominant interference39 corresponds to the 50 limit of the
region in which MCDS nonsense mutations have been
characterized13 (Figure 4), and stop codons downstream
of this region, corresponding to the MCDS mutation do-
main, would result in the production of truncated collagen
X that could interact with normal collagen X and exert
a dominant-negative effect if nonsense mRNA decay was
not complete. Although we have shown complete decay
of mutant collagen X mRNA in cartilage from two pa-
tients,14,15 other studies on a patient mutation at codon
663 indicate that signiﬁcant amounts of mutant mRNA
escape decay and produce abnormal truncated collagen X.
Recent studies have shown in a mouse model of MCDS
that the truncated protein produced as a result of a frame-
shift mutation generating a premature stop at codon 621
was retainedwithin the hypertrophic chondrocytes and ac-
tivated the unfolded protein response.16 Such an ER-stress
response has been previously described forMCDSmissense
mutations in which structural mutations in the NC1 do-
main prevent normal protein folding.22,40 The unfolded
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mutations has signiﬁcant downstream consequences on
gene expression in thehypertrophic chondrocytes, disrupt-
ing cellular differentiation and the coordination of the en-
dochondral ossiﬁcation program, and thus contributes to
the chondrodysplasia phenotype.22 The unfolded protein
response recently described for the truncated protein pro-
duced by the premature stop at codon 62116 also disrupts
hypertrophic-chondrocyte differentiation. These data
clearly suggest that although nonsense mutations result
in mRNA decay and reduced collagen X, the mutant trun-
cated protein produced from mRNA that escapes the
mRNA-surveillance-quality process can exert a signiﬁcant
gain-of-function effect, by unleashing the unfolded protein
response with deleterious downstream effects on cellular
expression and function.
The relative contribution of mRNA-decay-induced hap-
loinsufﬁciency14,15 and dominant interference16 to the
MCDS clinical phenotype is currently unknown and will
require the analysis of further patient and mouse model
cartilage-tissue samples. It is rare for NMD to completely
remove the mutant mRNA, and residual levels of 10%–
20% mutant mRNA are common for nonsense mutations
in other genes.1 In addition, recent studies on collagen
VI nonsense mutations41,42 have shown that haploinsufﬁ-
ciency of collagen VI can either be asymptomatic or cause
Bethlem myopathy, suggesting that different genetic back-
grounds, or polymorphisms, can inﬂuence the clinical
consequences of haploinsufﬁciency. We suggest that it is
likely that the most common outcome of MCDS nonsense
mutations is not haploinsufﬁciency from complete mRNA
decay but reduced collagen X resulting from partial decay
in combination with the production of some mutant trun-
cated collagen X. This truncated collagen has aberrant
folding properties that can dominantly interfere with nor-
mal collagen X assembly as well as induce a deleterious
cellular unfolded protein response, contributing further
to the chondrodysplasia phenotype.
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